Skip to main content

Lassa Virus Infection

1
Pipeline Programs
4
Companies
6
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

4 companies ranked by most advanced pipeline stage

Arisan Therapeutics
Arisan TherapeuticsCA - Carlsbad
1 program
1
ARN-75039Phase 13 trials
Active Trials
NCT07419373Recruiting135Est. Jun 2027
NCT06911242Completed16Est. Apr 2025
NCT05735249Completed94Est. Mar 2025
Allergy Therapeutics
Allergy TherapeuticsUK - West Sussex
2 programs
Prevalence and Incidence of Lassa Virus Infection in Southern MaliN/A1 trial
Seroprevalence and Incidence of Lassa Fever in the Rural Commune of Sibirila, District of Bougouni, N/A1 trial
Active Trials
NCT03783143Completed8,524Est. Jul 2024
NCT02311387Completed601Est. Oct 2018
United Therapeutics
United TherapeuticsMD - Silver Spring
1 program
ARN-75039 oral capsulesPHASE_1
Harmony Biosciences
Harmony BiosciencesPLYMOUTH MEETING, PA
1 program
MV-LASVPHASE_11 trial
Active Trials
NCT04055454Completed60Est. Jan 2021

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
Arisan TherapeuticsARN-75039
Arisan TherapeuticsARN-75039
Arisan TherapeuticsARN-75039
Harmony BiosciencesMV-LASV
Allergy TherapeuticsPrevalence and Incidence of Lassa Virus Infection in Southern Mali
Allergy TherapeuticsSeroprevalence and Incidence of Lassa Fever in the Rural Commune of Sibirila, District of Bougouni,

Clinical Trials (6)

Total enrollment: 9,430 patients across 6 trials

NCT07419373Arisan TherapeuticsARN-75039

ARN-75039 Lassa Fever Treatment in West Africa

Start: Feb 2026Est. completion: Jun 2027135 patients
Phase 2Recruiting
NCT06911242Arisan TherapeuticsARN-75039

A Comparison of the Pharmacokinetic Properties of ARN-75039 Tablets With Excipients to Neat ARN-75039 in Hydroxypropyl Methylcellulose (HPMC) Capsules in Healthy Adult Participants Under Fed Conditions

Start: Feb 2025Est. completion: Apr 202516 patients
Phase 1Completed
NCT05735249Arisan TherapeuticsARN-75039

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Oral ARN-75039 in Healthy Adult Subjects

Start: Jan 2023Est. completion: Mar 202594 patients
Phase 1Completed
NCT04055454Harmony BiosciencesMV-LASV

A Trial to Evaluate the Optimal Dose of MV-LASV (V182-001)

Start: Sep 2019Est. completion: Jan 202160 patients
Phase 1Completed
NCT03783143Allergy TherapeuticsPrevalence and Incidence of Lassa Virus Infection in Southern Mali

Prevalence and Incidence of Lassa Virus Infection in Southern Mali

Start: Dec 2020Est. completion: Jul 20248,524 patients
N/ACompleted
NCT02311387Allergy TherapeuticsSeroprevalence and Incidence of Lassa Fever in the Rural Commune of Sibirila, District of Bougouni,

Seroprevalence and Incidence of Lassa Fever in the Rural Commune of Sibirila, District of Bougouni, Mali

Start: Dec 2014Est. completion: Oct 2018601 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 actively recruiting trials targeting 9,430 patients
4 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.